quantum-computing

DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy

ALLISON GATLIN

2 min read

0 likes

⚡ Quantum Brief

Biotech firm DBV Technologies saw shares surge up to 46% to a three-year high after unveiling promising clinical results for its peanut allergy treatment in children aged 4–7. The treatment uses a skin patch delivering microdoses of peanut protein, aiming to gradually reprogram the immune system to tolerate peanuts over time. Phase 3 trial data, released in December 2025, demonstrated significant efficacy in reducing allergic reactions, though full details and long-term safety metrics remain undisclosed. The approach contrasts with traditional oral immunotherapy, potentially offering a non-invasive alternative for young children with severe peanut allergies. Analysts note the stock rally reflects investor optimism, but FDA approval and commercial viability hinge on further validation of the patch’s safety and scalability.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

FEATURED: How Quantum Computing Could Bring Crypto ChaosShares of DBV Technologies (DBVT) launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is developing a patch that delivers micro amounts of peanut protein through the skin. In theory, the small amounts of protein over time help reprogram the immune system to… 7/05/2019 Shares of Karyopharm Therapeutics reversed an early pop Friday after gaining FDA approval for a drug called Xpovio as a... 7/05/2019 Shares of Karyopharm Therapeutics reversed an early pop Friday after... Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!Get market updates, educational videos, webinars, and stock analysis.Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.©2025 Investor’s Business Daily, LLC.

Read Original

Source Information

Source: Investor's Business Daily

Website: https://www.investors.com/feed/

Discussion

0 professional contributions

Be the first to add a constructive contribution.